相关实验视频

Updated: Jul 2, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

一种基于风险分层的新型免疫调节治疗策略,用于治疗Vogt-Koyanagi-Harada疾病

Kehan Jin¹, Anyi Liang², Hang Song¹

¹From the Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (K.J., H.S., F.X., F.G., X.H., M.Z., C.Z.), Beijing; Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College (K.J., H.S., F.X., F.G., X.H., M.Z., C.Z.), Beijing.

American journal of ophthalmology

|February 18, 2024

概括

一个新的风险分层系统确定了高风险的Vogt-Koyanagi-Harada (VKH) 患者,他们从即时免疫调节治疗 (IMT) 中受益,改善视觉结果并减少复发,与按需治疗相比.

科学领域:

眼科医生眼科眼科
免疫学免疫学免疫学
临床医学临床医学

背景情况:

沃格特-科亚纳吉-哈拉达病 (VKH) 是一种系统性自身免疫性疾病,影响眼睛和神经组织.
目前对VKH的免疫调节治疗 (IMT) 策略缺乏个性化风险分层.
有效的风险分层对于定制治疗和改善患者预后至关重要.

研究的目的:

为Vogt-Koyanagi-Harada (VKH) 患者开发和验证一种新的两臂风险分层系统.
根据风险分层来评估定制免疫调节治疗 (IMT) 策略的有效性.
为了比较不同风险组的即时IMT和按需 (PRN) 方案之间的结果.

主要方法:

79名急性阶段VKH患者的回顾性队列研究.
根据风险因素,患者分为低风险 (n=58) 和高风险 (n=21) 组.
治疗比较:口服葡萄皮质激素 (GCs) 加PRN或一线IMT;最佳校正视力敏度 (BCVA),日落发光底部 (SGF),复发率和不良事件的评估.

主要成果:

与低风险患者相比,高风险的VKH患者表现出较差的基线BCVA,更高的SGF发病率和更高的复发率.
在低风险患者中,在PRN和即时IMT策略之间没有发现显著差异.
高风险患者的IMT立即改善了BCVA,降低了SGF,并降低了复发率与PRN相比,尽管系统性不良事件增加.

结论:

基线风险分层是VKH疾病预后不佳的重要预测因素.
立即IMT对高风险VKH患者有益,改善视觉结果并减少疾病复发.
建议基于风险分层的定制IMT策略,以实现最佳的VKH患者管理.

更多相关视频

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...